Leukemia, Cancer research, Myeloid leukemia, Molecular biology and Immunology are his primary areas of study. Bjørn Tore Gjertsen interconnects Myeloid and Toxicity in the investigation of issues within Leukemia. His Cancer research study integrates concerns from other disciplines, such as Mutation, Breast cancer, Gene expression and Chemokine receptor.
Bjørn Tore Gjertsen has included themes like Regulation of gene expression, Fms-Like Tyrosine Kinase 3 and Pharmacology in his Myeloid leukemia study. His research integrates issues of Cancer cell, Cell and Autocrine signalling in his study of Regulation of gene expression. His Immunology research includes themes of Internal medicine, Angiogenesis and Haematopoiesis.
His scientific interests lie mostly in Cancer research, Myeloid leukemia, Leukemia, Internal medicine and Immunology. His study in Cancer research is interdisciplinary in nature, drawing from both Cell culture, Apoptosis, Signal transduction, Stem cell and Bone marrow. His work in Myeloid leukemia addresses issues such as Pharmacology, which are connected to fields such as Targeted therapy.
In his work, Bioinformatics and Regulation of gene expression is strongly intertwined with Myeloid, which is a subfield of Leukemia. His Internal medicine research integrates issues from Gastroenterology and Oncology. The study incorporates disciplines such as Progenitor cell, Disease and Chemotherapy in addition to Immunology.
Bjørn Tore Gjertsen mainly investigates Cancer research, Myeloid leukemia, Internal medicine, Oncology and Cell culture. His Cancer research research incorporates themes from Tyrosine kinase, Ovarian cancer, Stem cell, Programmed cell death and In vivo. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Apoptosis, Leukemia, Retinoic acid and Bone marrow.
His Leukemia study frequently involves adjacent topics like Myeloid. His Oncology research is multidisciplinary, incorporating elements of Cancer, Chemotherapy regimen, Mutation, Immune system and Cohort. The concepts of his Cell culture study are interwoven with issues in Cell, Methylation, Bortezomib and Gene isoform.
His primary scientific interests are in Cancer research, Myeloid leukemia, Internal medicine, Oncology and Leukemia. His Cancer research research is multidisciplinary, relying on both Cell culture, Cell, Methylation, In vivo and Immunotherapy. His In vivo research incorporates elements of Cancer cell and Protein kinase B.
The Myeloid leukemia study combines topics in areas such as Apoptosis, Lipid metabolism, Retinoic acid and Fatty acid metabolism. His work deals with themes such as Progressive disease, Progression-free survival, Lactate dehydrogenase, Bevacizumab and Metastatic malignant melanoma, which intersect with Oncology. His work carried out in the field of Leukemia brings together such families of science as Myeloid, Gastroenterology, Adverse effect, Philadelphia chromosome and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells
Jonathan M Irish;Randi Hovland;Peter O Krutzik;Omar D Perez.
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.
Christine Gjerdrum;Crina Tiron;Torill Høiby;Ingunn Stefansson.
Proceedings of the National Academy of Sciences of the United States of America (2010)
The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells.
Roald Bøe;Bjørn Tore Gjertsen;Olav Karsten Vintermyr;Gunnar Houge.
Experimental Cell Research (1991)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska;Mika Kontro;Bhagwan Yadav;Henrik Edgren.
Cancer Discovery (2013)
Inherited Mutations in PTEN That Are Associated with Breast Cancer, Cowden Disease, and Juvenile Polyposis
Eric D. Lynch;Elizabeth A. Ostermeyer;Ming K. Lee;J. Fernando Arena.
American Journal of Human Genetics (1997)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
Sigbjørn Berentsen;Elling Ulvestad;Bjørn Tore Gjertsen;Henrik Hjorth-Hansen.
Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. Basal cAMP-kinase activity modulates interleukin-1 beta action.
B T Gjertsen;G Mellgren;A Otten;E Maronde.
Journal of Biological Chemistry (1995)
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
Georg Gjorgji Dimcevski;Spiros Kotopoulis;Tormod Karlsen Bjånes;Dag Hoem.
Journal of Controlled Release (2016)
SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells
Ling Li;Tereza Osdal;Yinwei Ho;Sookhee Chun.
Cell Stem Cell (2014)
The genetic subtypes of cAMP-dependent protein kinase--functionally different or redundant?
Stein O. Døskeland;Erik Maronde;Bjørn T. Gjertsen.
Biochimica et Biophysica Acta (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: